lilly tirzepatide approval Eli seeks FDA for weight loss drug Tirzepatide approved for obesity by

References Sean Wharton et al, Once-weekly semaglutide 72 mg in adults with obesity (STEP UP): a randomized, controlled, phase 3b trial, The Lancet Diabetes and Endocrinology, Volume 13, Issue 11p949-963November 2025, DOI: 10.1016/S2213-8587(25)00226-8 Higher dose of semaglutide provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA, Press Release, and Novo Nordisk Wharton, S, et al

Reconstitution : Allow both the peptide vial and the mixing solution (e.g., bacteriostatic water) to reach room temperature before mixing

Look for cloudiness, visible particles, discoloration, or an unusual smell

The skin parameters were measured by corneometer (hydration), tewameter (TEWL), an Antera 3D system (wrinkles), and elasticity (cutometer) at baseline and day 42 and day 84 in the treatment groups ( n = 36 treatment